Engineering higher affinity T cell receptors using a T cell display system

Journal of Immunological Methods

Volumn 339, Issue 2, 2008, Pages 175-184

  Chervin, Adam S ^a   Aggen, David H ^a   Raseman, John M ^a   Kranz, David M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Affinity; Peptide MHC; Protein engineering; Retroviral vectors; T cell receptors

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOMEDICAL ENGINEERING; CELL CLONE; CELL ISOLATION; CELL SURFACE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DNA LIBRARY; FLOW CYTOMETRY; GENETIC TRANSDUCTION; HYBRIDOMA; IMMUNOASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD8; COMPLEMENTARITY DETERMINING REGIONS; GENETIC VECTORS; HYBRIDOMAS; MICE; OLIGOPEPTIDES; PROTEIN ENGINEERING; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 55749084891     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2008.09.016     Document Type: Article

References (59)

1. Alam S.M., Travers P.J., Wung J.L., Nasholds W., Redpath S., Jameson S.C., and Gascoigne N.R. T-cell-receptor affinity and thymocyte positive selection. Nature 381 (1996) 616-620
2. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., and Gajewski T.F. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64 (2004) 1140-1145
3. Blattman J.N., and Greenberg P.D. Cancer immunotherapy: a treatment for the masses. Science 305 (2004) 200-205
4. Boder E.T., and Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15 (1997) 553-557
5. Boulter J.M., and Jakobsen B.K. Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens. Clin. Exp. Immunol. 142 (2005) 454-460
6. Call M.E., and Wucherpfennig K.W. The T cell receptor: critical role of the membrane environment in receptor assembly and function. Annu. Rev. Immunol. 23 (2005) 101-125
7. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
8. Cho B.K., Lian K.C., Lee P., Brunmark A., McKinley C., Chen J., Kranz D.M., and Eisen H.N. Differences in antigen recognition and cytolytic activity of CD8(+) and CD8(-) T cells that express the same antigen-specific receptor. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1723-1727
9. Daniels M.A., and Jameson S.C. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J. Exp. Med. 191 (2000) 335-346
10. Daniels M.A., Teixeiro E., Gill J., Hausmann B., Roubaty D., Holmberg K., Werlen G., Hollander G.A., Gascoigne N.R., and Palmer E. Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature 444 (2006) 724-729
11. Davis M.M., Boniface J.J., Reich Z., Lyons D., Hampl J., Arden B., and Chien Y. Ligand recognition by alpha beta T cell receptors. Annu. Rev. Immunol. 16 (1998) 523-544
12. Degano M., Garcia K.C., Apostolopoulos V., Rudolph M.G., Teyton L., and Wilson I.A. A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. Immunity 12 (2000) 251-261
13. Dudley M.E., and Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev., Cancer 3 (2003) 666-675
14. Engels B., and Uckert W. Redirecting T lymphocyte specificity by T cell receptor gene transfer-a new era for immunotherapy. Mol. Aspects Med. 28 (2007) 115-142
15. Gai S.A., and Wittrup K.D. Yeast surface display for protein engineering and characterization. Curr. Opin. Struct. Biol. 17 (2007) 467-473
16. Gallegos A.M., and Bevan M.J. Central tolerance: good but imperfect. Immunol. Rev. 209 (2006) 290-296
17. Garcia K.C., Tallquist M.D., Pease L.R., Brunmark A., Scott C.A., Degano M., Stura E.A., Peterson P.A., Wilson I.A., and Teyton L. Alphabeta T cell receptor interactions with syngeneic and allogeneic ligands: affinity measurements and crystallization. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13838-13843
18. Garcia K.C., Teyton L., and Wilson I.A. Structural basis of T cell recognition. Annu. Rev. Immunol. 17 (1999) 369-397
19. Gorski J., Yassai M., Zhu X., Kissela B., Kissella B., Keever C., and Flomenberg N. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J. Immunol. 152 (1994) 5109-5119
20. Ho W.Y., Blattman J.N., Dossett M.L., Yee C., and Greenberg P.D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3 (2003) 431-437
21. Hogquist K.A., Baldwin T.A., and Jameson S.C. Central tolerance: learning self-control in the thymus. Nat. Rev., Immunol. 5 (2005) 772-782
22. Holler P.D., and Kranz D.M. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18 (2003) 255-264
23. Holler P.D., Holman P.O., Shusta E.V., O'Herrin S., Wittrup K.D., and Kranz D.M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5387-5392
24. Holler P.D., Lim A.R., Cho B.K., Rund L.A., and Kranz D.M. CD8(-) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. J. Exp. Med. 194 (2001) 1043-1052
25. Holler P.D., Chlewicki L.K., and Kranz D.M. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4 (2003) 55-62
26. Jones L.L., Brophy S.E., Bankovich A.J., Colf L.A., Hanick N.A., Garcia K.C., and Kranz D.M. Engineering and characterization of a stabilized alpha1/alpha2 module of the class I major histocompatibility complex product Ld. J. Biol. Chem. 281 (2006) 25734-25744
27. Jones, L.L., Colf, L.A., Stone, J.D.,Garcia, K.C., Kranz, D.M., in press. Distinct CDR3 conformations in T cell receptors determine the level of cross-reactivity for diverse antigens, but not the docking orientation. J. Immunol.
28. Kappler J.W., Roehm N., and Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 49 (1987) 273-280
29. Kearse K.P., Roberts J.L., and Singer A. TCR alpha-CD3 delta epsilon association is the initial step in alpha beta dimer formation in murine T cells and is limiting in immature CD4+ CD8+ thymocytes. Immunity 2 (1995) 391-399
30. Kessels H.W., van Den Boom M.D., Spits H., Hooijberg E., and Schumacher T.N. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14578-14583
31. Kieke M.C., Shusta E.V., Boder E.T., Teyton L., Wittrup K.D., and Kranz D.M. Selection of functional T cell receptor mutants from a yeast surface-display library. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 5651-5656
32. Kranz D.M., Tonegawa S., and Eisen H.N. Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 7922-7926
33. Kuhns M.S., Davis M.M., and Garcia K.C. Deconstructing the form and function of the TCR/CD3 complex. Immunity 24 (2006) 133-139
34. Letourneur F., and Malissen B. Derivation of a T cell hybridoma variant deprived of functional T cell receptor alpha and beta chain transcripts reveals a nonfunctional alpha-mRNA of BW5147 origin. Eur. J. Immunol. 19 (1989) 2269-2274
35. Li Y., Moysey R., Molloy P.E., Vuidepot A.L., Mahon T., Baston E., Dunn S., Liddy N., Jacob J., Jakobsen B.K., and Boulter J.M. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23 (2005) 349-354
36. Lipovsek D., Lippow S.M., Hackel B.J., Gregson M.W., Cheng P., Kapila A., and Wittrup K.D. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J. Mol. Biol. 368 (2007) 1024-1041
37. Matsui K., Boniface J.J., Steffner P., Reay P.A., and Davis M.M. Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 12862-12866
38. Molloy P.E., Sewell A.K., and Jakobsen B.K. Soluble T cell receptors: novel immunotherapies. Curr. Opin. Pharmacol. 5 (2005) 438-443
39. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., and Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
40. Richman S.A., and Kranz D.M. Display, engineering, and applications of antigen-specific T cell receptors. Biomol. Eng. 24 (2007) 361-373
41. Richman, S.A., Aggen, D.H., Dossett, M.L., Donermeyer, D.L., Allen, P.M., Greenberg, P.D., Kranz, D.M., 2008. Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain VαVβ fragments. Mol. Immunol. doi:10.1016/j.molimm.2008.09.021.
42. Robbins P.F., Li Y.F., El-Gamil M., Zhao Y., Wargo J.A., Zheng Z., Xu H., Morgan R.A., Feldman S.A., Johnson L.A., Bennett A.D., Dunn S.M., Mahon T.M., Jakobsen B.K., and Rosenberg S.A. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180 (2008) 6116-6131
43. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., and Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev., Cancer 8 (2008) 299-308
44. Rudolph M.G., Stanfield R.L., and Wilson I.A. How TCRs bind MHCs, peptides, and coreceptors. Annu. Rev. Immunol. 24 (2006) 419-466
45. Russell S.J., Hawkins R.E., and Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21 (1993) 1081-1085
46. Schodin B.A., Tsomides T.J., and Kranz D.M. Correlation between the number of T cell receptors required for T cell activation and TCR-ligand affinity. Immunity 5 (1996) 137-146
47. Schumacher T.N. T-cell-receptor gene therapy. Nat. Rev., Immunol. 2 (2002) 512-519
48. Shusta E.V., Holler P.D., Kieke M.C., Kranz D.M., and Wittrup K.D. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat. Biotechnol. 18 (2000) 754-759
49. Spiotto M.T., Yu P., Rowley D.A., Nishimura M.I., Meredith S.C., Gajewski T.F., Fu Y.X., and Schreiber H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17 (2002) 737-747
50. Sykulev Y., Brunmark A., Jackson M., Cohen R.J., Peterson P.A., and Eisen H.N. Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes. Immunity 1 (1994) 15-22
51. Tereshko V., Uysal S., Koide A., Margalef K., Koide S., and Kossiakoff A.A. Toward chaperone-assisted crystallography: protein engineering enhancement of crystal packing and X-ray phasing capabilities of a camelid single-domain antibody (VHH) scaffold. Protein Sci. 17 (2008) 1175-1187
52. Thomas D.L., Kranz D.M., and Roy E.J. Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors. Cancer Immunol. Immunother. 57 (2008) 1323-1333
53. Udaka K., Wiesmuller K.H., Kienle S., Jung G., and Walden P. Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J Immunol 157 (1996) 670-678
54. Urban J.H., Schneider R.M., Compte M., Finger C., Cichutek K., Alvarez-Vallina L., and Buchholz C.J. Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Res. 33 (2005) e35
55. van der Merwe P.A., and Davis S.J. Molecular interactions mediating T cell antigen recognition. Annu. Rev. Immunol. 21 (2003) 659-684
56. Weber K.S., Donermeyer D.L., Allen P.M., and Kranz D.M. Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 19033-19038
57. Wegener A.M., Letourneur F., Hoeveler A., Brocker T., Luton F., and Malissen B. The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell 68 (1992) 83-95
58. Zhang B., Bowerman N.A., Salama J.K., Schmidt H., Spiotto M.T., Schietinger A., Yu P., Fu Y.X., Weichselbaum R.R., Rowley D.A., Kranz D.M., and Schreiber H. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204 (2007) 49-55
59. Zhang B., Karrison T., Rowley D.A., and Schreiber H. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 118 (2008) 1398-1404